In one such study [124], targeting survivin, a member of the inhibitor of apoptosis protein (IAP) family, using HIV-1 TAT peptides to disrupt the phosphorylation of survivin by cyclin-dependent kinase 1 abrogated the TCS response seen in H1299 lung cancer cells that had been treated with the anticancer drug camptothecin and instead triggered an apoptotic response. The gene discussed is BIRC5; the disease is lung cancer.